Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

Cannot have received: XL092 (XL092)

Prior treatment with XL092

Cannot have received: PD-1 inhibitor

Prior treatment with PD-1/PD-L1 or CTLA-4 inhibitors

Cannot have received: PD-L1 inhibitor

Prior treatment with PD-1/PD-L1 or CTLA-4 inhibitors

Cannot have received: CTLA-4 inhibitor

Prior treatment with PD-1/PD-L1 or CTLA-4 inhibitors

Cannot have received: MET inhibitor (cabozantinib)

Receipt of any type of small molecule kinase inhibitor such as cabozantinib or other MET or Dual MET/HGF monoclonal antibodies or MET/HGF tyrosine kinase inhibitors (TKIs), or any other VEGFR TKIs (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment.

Cannot have received: VEGFR inhibitor

any other VEGFR TKIs (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment

Cannot have received: cytotoxic chemotherapy

Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment.

Cannot have received: biologic therapy

Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment.

Cannot have received: systemic anticancer therapy

Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment.

Cannot have received: radiation therapy

Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before first dose of study treatment.

Cannot have received: radionuclide therapy

Systemic treatment with radionuclides within 6 weeks before first dose of study treatment.

Cannot have received: local anticancer therapy (surgery, thermal ablation, radiofrequency ablation, microwave ablation, transarterial chemoembolization, transarterial radioembolization)

Subjects who have received any local anticancer therapy including surgery, regional ablative therapies including thermal ablation, radiofrequency ablation (RFA), Microwave Ablation (MWA) transarterial chemoembolization (TACE), or transarterial radioembolization (TARE) within 28 days prior to first dose of study treatment.